Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Thyroid Gland Disorders Market $2.7 Billion by 2027

The global market for thyroid gland disorders estimated to reach $2.7 billion by 2027, growing at a CAGR of 3.3% over the forecast period, driven by increasing incidence of thyroid gland disorders, and other conditions such as obesity, diabetes, and cardiovascular diseases.

Global Thyroid Gland Disorders Market

Iodine nutrition is a key determinant of thyroid disease risk; however, other factors, such as ageing, smoking status, genetic susceptibility, ethnicity, endocrine disruptors and the advent of novel therapeutics, including immune checkpoint inhibitors, also influence thyroid disease epidemiology.

  • Hypothyroidism and hyperthyroidism are common conditions with potentially devastating health consequences that affect all populations worldwide.

In the developed world, the prevalence of undiagnosed thyroid disease is likely falling owing to widespread thyroid function testing and relatively low thresholds for treatment initiation.

  • However, continued vigilance against iodine deficiency remains essential in developed countries, particularly in Europe.
    • The prevalence and incidence of thyroid dysfunction are difficult to compare across countries owing to differences in diagnostic thresholds, assay sensitivities, population selection and fluxes in iodine nutrition and population dynamics.

In iodine-sufficient areas, the majority of thyroid dysfunction is due to thyroid autoimmunity, and data from Europe and other parts of the world have revealed the influence of variation in iodine status and the impact of iodine supplementation on the epidemiology of thyroid dysfunction.

  • Other factors that can affect the epidemiology of thyroid disease are the increasingly widespread use of thyroid function testing, lowering of treatment thresholds and introduction of novel therapeutic agents that can affect thyroid function.
Prevalence of Hyperthyroidism

The prevalence of overt hyperthyroidism ranges from 0.2% to 1.3% in iodine-sufficient parts of the world. The prevalence of overt hyperthyroidism is roughly similar in Europe and the United States.

  • Almost one-third of the world’s population lives in areas of iodine deficiency. The prevalence of overt hypothyroidism in the general population ranges from between 0.2% and 5.3% in Europe and 0.3% and 3.7% in the USA.
    • Hypothyroidism is common throughout the world and is particularly common in the UK.
Prevalence of Hypothyroidism

The global thyroid gland disorders treatment market report estimates the market size ($million 2017 to 2027), market share, growth trends and forecast (CAGR% 2021 to 2027).

The global market for thyroid gland disorders (drugs) segmented by disorder (drug class/product) type [hyperthyroidism (imidazole, propacil), hypothyroidism (levothyroxine, liothyronine), and geography.

  • Based on the type of disorder, the hypothyroidism segment accounted for the largest share of the total thyroid gland disorders treatment market, accounting for more than 75% of the global share, and also expected to dominate the market during the forecast period.
    • The dominance of hypothyroidism segment is attributed to increasing incidence of hypothyroidism and subsequent higher demand for hypothyroid therapeutics in the developed regions.
      • The Levothyroxine drug class segment held the largest share of total market, attributed to increasing hypothyroidism incidence and patient preference for Levothyroxine drugs such as Synthroid and Euthyrox.
  • The hyperthyroidism drug, Propacil segment accounted for the lowest share of the global market and is estimated to decline at a negative growth rate during the forecast period.
    • The decreasing revenue growth attributed to potential side effects such as liver damage, stomach upset, muscle and joint pains and higher patient preference for Imidazole drugs for hyperthyroidism.

The global market for thyroid gland disorders is further divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA) and Rest of the World.

  • In terms of geography, the North America region dominated the global market, followed by Europe and is expected to held the largest revenue share of the market during the forecast period.
    • Increasing healthcare expenditure and rising thyroid gland disorders are propelling the market in North America.
      • Hypothyroidism drugs accounted for more than 75% share of the North America market, owing to higher demand for drugs such as Synthroid and Euthyrox in the developed regions.
  • On the other hand, the market in Asia Pacific region expected to expand at the highest CAGR throughout the coming years.
    • Growing presence of major players in this region and increasing geriatric population predicted to boost the market in emerging economies.

The report also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends.

Major competitors operating in the global market for thyroid gland disorders and included in this report are Abbott Laboratories, Inc., AbbVie, Inc., Allergan plc, GlaxoSmithKline plc, Lannett Company, Inc., Merck & Co., Inc., Mylan N.V., Novartis International AG, Pfizer, Inc., Sanofi S.A., and Takeda Pharmaceutical Co., Ltd.

  • Disorder (Drug Class/Product)
    • Hyperthyroidism
      • Imidazole
      • Propacil
    • Hypothyroidism
      • Levothyroxine
      • Liothyronine
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Abbott Laboratories, Inc.
    • AbbVie, Inc.
    • Allergan plc
    • GlaxoSmithKline plc
    • Lannett Company, Inc.
    • Merck & Co., Inc.
    • Mylan N.V.
    • Novartis International AG
    • Pfizer, Inc.
    • Sanofi S.A.
    • Takeda Pharmaceutical Co., Ltd.

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/thyroid-gland-disorders-treatment-market/

Related publications:



    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]

    Subject*

    Message*

    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 463-5840
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: [email protected]